

FORM PTO-1390 (Modified) (REV 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 113.1010	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR To Be Assigned 09/787559	
INTERNATIONAL APPLICATION NO. PCT/DE99/02865		INTERNATIONAL FILING DATE September 6, 1999		PRIORITY DATE CLAIMED September 19, 1998	
TITLE OF INVENTION REGULATORY PROTEIN FROM HUMAN KERATINOCYTES					
APPLICANT(S) FOR DO/EO/US Michael BECHTEL, Jeanette REINARTZ, Birgit SCHAEFER & Reinhard WALLICH					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). 8. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 9. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 10. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 					
Items 13 to 20 below concern document(s) or information included:					
<ol style="list-style-type: none"> 13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter. 19. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail 20. <input checked="" type="checkbox"/> Other items or information: <div style="border: 1px solid black; padding: 10px; margin-top: 10px;"> <p> - Letter re: Priority - Postcard - Sequence Listing Diskette </p> </div> 					

U.S. APPLICATION NO. (IF KNOWN - SEE 37 CFR 1.53) 09/1787559	INTERNATIONAL APPLICATION NO. PCT/DE99/02865	ATTORNEY'S DOCKET NUMBER 113.1010
--	--	---

21. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO **\$1,000.00**
- ☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **\$860.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **\$710.00**
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) **\$690.00**
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) **\$100.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =**\$860.00**

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☒ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$130.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	19 - 20 =	0	x \$18.00	\$0.00	
Independent claims	3 - 3 =	0	x \$78.00	\$0.00	
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$990.00	

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). ☐

\$0.00**SUBTOTAL =****\$990.00**

Processing fee of **\$130.00** for furnishing the English translation later than ☒ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$130.00**TOTAL NATIONAL FEE =****\$1,120.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐

\$0.00**TOTAL FEES ENCLOSED =****\$1,120.00**

Amount to be refunded	\$
charged	\$

☒ A check in the amount of **\$1,120.00** to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.

A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **50-0552** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Clifford M. Davidson, Esq.
DAVIDSON, DAVIDSON & KAPPEL
485 Seventh Avenue, 14th Floor
New York, New York 10018
Tel: (212) 736-1940
Fax: (212) 736-2427

**23280**

PATENT TRADEMARK OFFICE

The PTO did not receive the following listed item(s)

SIGNATURE

William C. Gehris


NAME

38,156

REGISTRATION NUMBER

March 19, 2001

DATE



Rec'd PCT/PTO 18 JUN 2001
09/787,559
113.1010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Application of: KRAMER et al.
Serial No.: 09/787,559
International
Application No.: PCT/DE99/02865
Filed: March 19, 2001
For: REGULATORY PROTEIN FROM HUMAN
KERATINOCYTES

BOX PCT
Asst. Commissioner for Patents
Washington, D.C. 20231

June 6, 2001

**PRELIMINARY AMENDMENT AND
RESPONSE TO SEQUENCE LISTING REQUIREMENT AND MISSING PARTS**

Sir:

Please make the following amendments prior to examination of this application:

IN THE SPECIFICATION:

Please **delete** the Paper Form of the Sequence Listing after Figure 14, pages 1/9 to 9/9, and **insert** the paper copy of the sequence listing, which is attached herewith, after Figure 14.

REMARKS

This submission is in response to the Notice to Comply with Sequence Listing Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated May 10, 2001, and the Notification of Missing Requirements under 37 C.F.R. § 371, dated May 10, 2001, copies of which are enclosed.

In response, Applicants herewith submit a Sequence Listing in paper form, in compliance with 37 C.F.R. §§ 1.821-1.825, and hereby request entry of the paper copy of the substitute

Sequence Listing into the specification. Applicants previously submitted a Sequence Listing in computer readable form on a 3.5 inch computer disk, at the time of filing the instant application.

Pursuant to 37 C.F.R. § 1.821(f) and (g), I hereby state that the information recorded in computer readable form is identical to the paper sequence listing. I hereby state that the submission herein does not include new matter.

Applicants also submit the enclosed executed declaration in response to the Notice of Missing Requirements. Applicants respectfully submit that the enclosed declaration complies with 37 C.F.R. § 1.497(a) and (b).

Applicants respectfully submit that the present amendment is responsive to the Notice of Missing Requirements, dated May 10, 2001, and the Notice to Comply with Sequence Listing Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated May 10, 2001.

CONCLUSION

Consideration of this application, as amended, is respectfully requested. No new matter has been added, and no new claims have been added. An early and favorable action on the merits is earnestly solicited.

Respectfully submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 

William C. Gehris
Reg. No. 38,156

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue - 14th Floor
New York, New York 10018
(212) 736-1940

VERSION OF SPECIFICATION
WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

Please **delete** the Paper Form of the Sequence Listing after Figure 14, pages 1/9 to 9/9,
and **insert** the paper copy of the sequence listing, which is attached herewith, after Figure 14.

UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Application of: KRAMER et al.
Serial No.: To Be Assigned
International
Application No.: PCT/DE99/02865
Filed: Herewith
For: REGULATORY PROTEIN FROM HUMAN
KERATINOCYTES

BOX PCT
Asst. Commissioner for Patents
Washington, D.C. 20231

March 19, 2001

PRELIMINARY AMENDMENT

Sir:

Applicants request that the following Amendments be made in the above-identified matter prior to examination thereof:

IN THE SPECIFICATION

Before paragraph [0001], please change the heading "Description" to --BACKGROUND INFORMATION--.

Before paragraph [0004], please insert the heading --SUMMARY OF THE INVENTION--.

After paragraph [0025], please insert the heading --BRIEF DESCRIPTION OF THE DRAWINGS--.

Please insert paragraphs 0025.1 to 0025.14 as follows:

[0025.1] Fig. 1 shows the results of a Northern blot, which was performed with mRNA from keratinocyte sheets (a) immediately after or (b) four hours after dispase-induced detachment.

[0025.2] Fig. 2 shows structural data for SEQ ID NO:2 .

[0025.3] Fig. 3 shows a Western blot from Example 3B(2).

[0025.4] Fig. 4 shows an immunoblot result from from Example 5.

- [0025.5] Fig. 5 shows results from Example 3A(1).
[0025.6] Fig. 6 shows results from Example 3B(3).
[0025.7] Fig. 7 shows results from Example 3B(4).
[0025.8] Fig. 8 shows vector pGEX.
[0025.9] Fig. 9 shows the pBK-CMV-pKe#122 vector.
[0025.10] Fig. 10 shows results from Example 3B(5).
[0025.11] Fig. 11 shows immunoblot results from Example 3(B)(5).
[0025.12] Fig. 12 shows results from Example 3B6 for subconfluent HaCaT cultures.
[0025.13] Fig. 13 shows results from Example 3B6 for confluent HaCaT cultures.
[0025.14] Fig. 14 shows structural data for SEQ ID NO:3.

Before paragraph [0026] insert the heading DETAILED DESCRIPTION.

Page 21, first line change "CLAIMS" to --WHAT IS CLAIMED IS--.

IN THE CLAIMS:

Please amend claims 1-6, 8-15, 17 and 19 as follows:

1. (Amended) Isolated polypeptide,
which is functionally identical to a protein that occurs naturally in human keratinocytes and is increasingly expressed when the keratinocytes are in an activated state, and
which has the amino acid sequence indicated in either the SEQ ID NO:2 sequence protocol or the SEQ ID NO:3 sequence protocol, or representing an allele or derivative obtained through amino acid substitution, deletion, insertion or inversion from one of these two amino acid sequences.

2. (Amended) Isolated nucleic acid
that encodes a protein,

which is functionally identical to a protein that occurs naturally in human keratinocytes and is increasingly expressed when the keratinocytes are in an activated state, which has the nucleotide sequence indicated in either the SEQ ID NO:1 sequence protocol or the SEQ ID NO:4 sequence protocol, or a nucleotide sequence complementary to one of these two, or a partial sequence of one of these two indicated or complementary nucleotide sequences, or a nucleotide sequence that hybridizes wholly or in part with one of these aforementioned nucleotide sequences.

3. (Amended) Isolated nucleic acid according to claim 2, wherein the nucleic acid is obtained from a natural, synthetic or half-synthetic source.
4. (Amended) Isolated nucleic acid according to claim 2 wherein the nucleic acid is a cDNA.
5. (Amended) Isolated nucleic acid according to claim 2 wherein the nucleic acid is a sense or antisense oligonucleotide, which encompasses at least 6 nucleotides, and hybridizes with the nucleotide sequence indicated in sequence protocol SEQ ID NO:1 or sequence protocol SEQ ID N:4 or partial sequences thereof.
6. (Amended) Isolated nucleic acid according to claim 2 wherein the nucleic acid is a splice variant, which hybridizes with the nucleotide sequence indicated in sequence protocol SEQ ID NO:1 or in sequence protocol SEQ ID NO:4.
8. (Amended) Recombinant DNS vector molecule, which encompasses a nucleic acid according to claim 2, and which has the ability to express a protein that occurs in human keratinocytes and is increasingly expressed when the keratinocytes are in an activated state, in particular protein pKe#122, in a prokaryotic or eukaryotic cell.

9. (Amended) Recombinant DNS vector molecule according to claim 8, wherein the vector molecule is the plasmid pUEX-1 or pGEX-2T or pBK-CMV or pHR2.
10. (Amended) Transformed host cell containing a nucleic acid according to claim 2, which is coupled with an activatable promotor contained in the host cell naturally or as the consequence of a recombination, and which has the ability to express a protein that occurs in human keratinocytes and is increasingly expressed when the keratinocytes are in an activated state, in particular protein pKe#122.
11. (Amended) Transformed host cell according to claim 10, wherein the promotor is the cytokeratin-14 promotor and the host cell is a keratinocyte, or that the promotor is the CMV promotor and the host cell is a Cos cell.
12. (Amended) Use of a nucleic acid according to claim 2 for manufacturing transgenic mammals, in particular mice or rats.
13. (Amended) Use of a polypeptide according to claim 1 for manufacturing an antibody against this polypeptide and/or proteins related thereto.
14. (Amended) Use according to claim 13, wherein the antibody is used for the diagnostic and/or therapeutic treatment in particular of dermatological diseases, or for the cosmetic treatment in particular of the epidermis.
15. (Amended) Antibody that reacts specifically with a polypeptide according to claim 1.
17. (Amended) Reagent for the indirect detection of a protein that occurs in human keratinocytes and is increasingly expressed in activated keratinocytes, in particular protein pKe#122, wherein the reagent encompasses at least one nucleic acid according to claim 2.

19. (Amended) Use of a polypeptide according to claim 1 for identifying substances with medical, cosmetic or pharmacological applications, which bind to the polypeptide or nucleic acid, and thereby influence its function and/or expression, in particular acting as inhibitors or activators.

Please add the following new claims:

20. (New) The nucleic acid as recited in claim 5 wherein the oligonucleotide includes 8 to 25 nucleotides.

21. (New) Use of a vector molecule according to claim 8 for manufacturing transgenic mammals, in particular mice or rats.

22. (New) Use of a polypeptide according to claim 7 for manufacturing an antibody against this polypeptide and/or proteins related thereto.

23. (New) Antibody that reacts specifically with a polypeptide according to claim 7.

24. (New) Reagent for the indirect detection of a protein that occurs in human keratinocytes and is increasingly expressed in activated keratinocytes, in particular protein pKe#122, wherein the reagent encompasses at least one nucleic acid according to claim 6.

25. (New) Reagent for the indirect detection of a protein that occurs in human keratinocytes and is increasingly expressed in activated keratinocytes, in particular protein pKe#122, wherein the reagent encompasses a polypeptide according to claim 1.

26. (New) Reagent for the indirect detection of a protein that occurs in human keratinocytes and is increasingly expressed in activated keratinocytes, in particular protein pKe#122, wherein the reagent encompasses a polypeptide according to claim 7.

27. (New) Use of a polypeptide according to claim 7 for identifying substances with medical, cosmetic or pharmacological applications, which bind to the polypeptide or nucleic acid, and thereby influence its function or expression, in particular acting as inhibitors or activators.

28. (New) Use of a nucleic acid according to claim 2 for identifying substances with medical, cosmetic or pharmacological applications, which bind to the polypeptide or nucleic acid, and thereby influence its function or expression, in particular acting as inhibitors or activators.

REMARKS


Consideration of this application, as amended, is respectfully requested.

Support for all new claims is found in the specification as originally filed. No new matter has been added, and no new claims have been added.

Applicants believe that no fees are due as a result of this amendment. In the event of a fee discrepancy, please charge our Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 
William C. Gehris
Reg. No. 38,156


Davidson, Davidson & Kappel, LLC
485 Seventh Avenue - 14th Floor
New York, New York 10018
(212) 736-1940

"Express Mail" mailing label no.: EL 743183923 US

Date of deposit: March 19, 2001

I hereby certify that this correspondence and/or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above in an envelope addressed to "Commissioner of Patents and Trademarks, Washington, DC 20231"

DAVIDSON, DAVIDSON & KAPPEL, LLC

BY: 
Samuel Gomez

**VERSION OF SPECIFICATION AND CLAIMS AMENDMENTS
WITH MARKINGS TO SHOW CHANGES MADE**

IN THE SPECIFICATION:

Page 1 before paragraph [0001]: --BACKGROUND INFORMATION--[Description]

Page 21 first line : --WHAT IS CLAIMED IS--[CLAIMS]

IN THE CLAIMS:

2. Isolated polypeptide,

which is functionally identical [or similar] to a protein that occurs naturally in human keratinocytes and is increasingly expressed when the keratinocytes are in an activated state, and

which has the amino acid sequence indicated in either the SEQ ID NO:2 sequence protocol or the SEQ ID NO:3 sequence protocol, or representing an allele or derivative obtained through amino acid substitution, deletion, insertion or inversion from one of these two amino acid sequences.

2. Isolated nucleic acid

that encodes a protein,

which is functionally identical [or similar] to a protein that occurs naturally in human keratinocytes and is increasingly expressed when the keratinocytes are in an activated state,

which has the nucleotide sequence indicated in either the SEQ ID NO:1 sequence protocol or the SEQ ID NO:4 sequence protocol,

or a nucleotide sequence complementary to one of these two,

or a partial sequence of one of these two indicated or complementary nucleotide sequences,

or a nucleotide sequence that hybridizes wholly or in part with one of these aforementioned nucleotide sequences.

3. Isolated nucleic acid according to claim 2, [characterized by the fact that this] wherein the nucleic acid is obtained from a natural, synthetic or half-synthetic source.
4. Isolated nucleic acid according to claim 2 [or 3, characterized by the fact that this] wherein the nucleic acid is a cDNA.
5. Isolated nucleic acid according to [one of claims 2 or 3, characterized by the fact that this] claim 2 wherein the nucleic acid is a sense or antisense oligonucleotide, which encompasses at least 6[, preferably 8 to 25] nucleotides, and hybridizes with the nucleotide sequence indicated in sequence protocol SEQ ID NO:1 or sequence protocol SEQ ID N:4 or partial sequences thereof.
6. Isolated nucleic acid according to [one of claims 2 or 3, characterized by the fact that this] claim 2 wherein the nucleic acid is a splice variant, which hybridizes with the nucleotide sequence indicated in sequence protocol SEQ ID NO:1 or in sequence protocol SEQ ID NO:4.
8. Recombinant DNS vector molecule, which encompasses a nucleic acid according to [one of claims 2 to 6] claim 2, and which has the ability to express a protein that occurs in human keratinocytes and is increasingly expressed when the keratinocytes are in an activated state, in particular protein pKe#122, in a prokaryotic or eukaryotic cell.
9. Recombinant DNS vector molecule according to claim 8, [characterized by the fact that] wherein the vector molecule is the plasmid pUEX-1 or pGEX-2T or pBK-CMV or pHR2.
10. Transformed host cell containing a nucleic acid according to [one of claims 2 to 6] claim 2, which is coupled with an activatable promotor contained in the host cell naturally or as the consequence of a recombination, and which has the ability to express a protein that occurs in human keratinocytes and is increasingly expressed when the keratinocytes are in an activated state, in particular protein pKe#122.
11. Transformed host cell according to claim 10, [characterized by the fact that] wherein the promotor is the cytokeratin-14 promotor and the host cell is a keratinocyte, or that the promotor is the CMV promotor and the host cell is a Cos cell.

12. Use of a nucleic acid according to claim 2 [or a vector molecule according to claim 8] for manufacturing transgenic mammals, in particular mice or rats.
13. Use of a polypeptide according to claim 1 [or claim 7] for manufacturing an antibody against this polypeptide and/or proteins related thereto.
14. Use according to claim 13, [characterized by the fact that] wherein the antibody is used for the diagnostic and/or therapeutic treatment in particular of dermatological diseases, or for the cosmetic treatment in particular of the epidermis.
15. Antibody that reacts specifically with a polypeptide according to claim 1 [or claim 7].
17. Reagent for the indirect detection of a protein that occurs in human keratinocytes and is increasingly expressed in activated keratinocytes, in particular protein pKe#122, [characterized by the fact that] wherein the reagent encompasses at least one nucleic acid according to claim 2 [one of claims 2 to 6 or a polypeptide according to claim 1 or claim 7].
19. Use of a polypeptide according to claim 1 [or claim 7 or a nucleic acid according to claim 2] for identifying substances with medical, cosmetic or pharmacological applications, which bind to the polypeptide or nucleic acid, and thereby influence its function and/or expression, in particular acting as inhibitors or activators.

REGULATORY PROTEIN FROM HUMAN KERATINOCYTESDescription

[0001] The invention relates to an isolated polypeptide that is identical or similar (i.e., the same in function and effect) to a protein that occurs naturally in human keratinocytes and is increasingly expressed when the keratinocytes are in an activated state. It also relates to an isolated nucleic acid, which codes a polypeptide or protein typical for human keratinocytes, and to the use of this polypeptide and this nucleic acid for detection, in particular diagnostic, and/or therapeutic purposes, and the use of reagents, in particular recombinant vector molecules and antibodies against such molecules.

[0002] Based on prior art as currently exists, essentially pharmaceuticals with a broad range of action are used in skin treatment to influence epidermal disturbances, e.g., autoimmune dermatoses „Pemphigus vulgaris“ and „Bullous Pemphigoid“, including locally or systemically applied glucocorticoids, vitamin A acid derivatives, antimetabolites and cytostatics, or more or less non-specific measures are used in treatment, such as „dye therapy“ or „light therapy“. However, the disadvantage to all known agents or measures is that they are not very specific, and hence of course bring about numerous side effects.

[0003] The preparation of more specific agents has thus far been unsuccessful due to a basic problem that has persisted in dermatology for a long time, namely that the number of cellular target molecules (target structures, targets) which might serve as a point of attack for exerting a (specific) influence on cellular metabolism, in particular from a medical or even cosmetic standpoint, is narrowly restricted in epidermal keratinocytes.

[0004] Therefore, the object of this invention is to provide new target structures in epidermal keratinocytes that can serve as a point of attack for diagnostic, therapeutic and cosmetic agents, or generally for influencing cellular metabolism.

[0005] One solution to this object involves preparing a protein of the kind mentioned at the outset, which is upwardly adjusted given activated keratinocytes, i.e., increasingly expressed or produced, and kept at a higher concentration level, and which has the amino acid sequence indicated in either the SEQ ID NO:2 sequence protocol or

the SEQ ID NO:3 sequence protocol, or an allele or derivative obtained through amino acid substitution, deletion, insertion or inversion from one of these two amino acid sequences. In the following, the polypeptide with the SEQ ID NO:2 or SEQ ID NO:3 amino acid sequence shall also be referred to as protein pKe#122.

[0006] Another solution to this object involves preparing an isolated nucleic acid that codes a protein, which is identical or similar to a protein that occurs naturally in human keratinocytes and is increasingly expressed when the keratinocytes are in an activated state, and which has the nucleotide sequence indicated in either the SEQ ID NO:1 sequence protocol or the SEQ ID NO:4 sequence protocol, or a nucleotide sequence complementary to one of these two, or a partial sequence of one of these two indicated or complementary nucleotide sequences, or a nucleotide sequence that hybridizes wholly or in part with one of these aforementioned nucleotide sequences, wherein „U“ can take the place of „T“ in these two sequence protocols. This group of nucleic acids or nucleotide sequences according to the invention also includes in particular splice variants and sense or antisense oligonucleotides, which hybridize with the nucleotide sequence indicated in the SEQ ID NO:1 sequence protocol or the SEQ ID NO:4 sequence protocol, preferably identical or complementary to at least one of these two.

[0007] As a result, the invention also encompasses proteins or polypeptides of the kind mentioned at the outset, which have an amino acid sequence that results from such a splice variant, in particular the splice variant of an mRNA, which is identical or complementary to the nucleotide sequence indicated in the SEQ ID NO:1 sequence protocol or the SEQ ID NO:4 sequence protocol.

[0008] The sense or antisense oligonucleotides according to the invention encompass at least 6, preferably 8 to 25 nucleotides.

[0009] The term „hybridized“ relates to the hybridization procedures known in the art under conventional, in particular also under highly stringent hybridization conditions. The expert selects the specific hybridization parameters based on the used nucleotide sequence and his or her general technical knowledge (compare: *Current Protocols in Molecular Biology*, Vol. 1, 1997, John Wiley & Sons Inc., Suppl. 37, Chapter 4.9.14). The nucleic acid(s) according to the invention can be obtained from both a natural source or synthetically or semi-synthetically. Its presentation as cDNA has proven to be particularly effective in practice.

[0010] The polypeptide that has the amino acid sequence according to SEQ ID NO:2 or SEQ ID NO:3 and is coded by the nucleic acid indicated in the SEQ ID NO:1 sequence protocol or the SEQ ID NO:4 sequence protocol, and that is referred to as protein pKe#122 below, is upwardly adjusted in human epidermal keratinocytes, namely increasingly expressed (produced) and kept at a significantly higher concentration level in comparison to the initial state if these cells are in the „activated“ state, i.e., in a state of proliferation and/or migration, among others, e.g., after an accidental skin injury or given an autoimmunologically induced bullous dermatoses „Pemphigus vulgaris“ (triggered by autoantibodies against desmosomes) and „Bullous Pemphigoid“ (triggered by autoantibodies against hemidesmosomes). The activated state of the human epidermal keratinocytes is also manifested in an elevated expression of known activation markers uPA (urokinase-type plasminogen activator) and uPA-R (receptor for urokinase-type plasminogen activator) relative to the resting state (initial state), and can be qualitatively and quantitatively detected based on these markers. (compare: Schäfer B.M., Reinartz J., Bechtel M.J., Inndorf S., Lang E., und Kramer M. D., 1996: *Dispase mediated basal detachment of cultured keratinocytes induces urokinase-type plasminogen activator (uPA) and its receptor (uPA-R, CD87)*, *Exp. Cell Res.* **228**, pp. 246-253).

[0011] Protein pKe#122 has a serine/threonine-kinase motif, several (four) tyrosine kinase phosphorylation motifs and a kinase domain with an ATP binding site. It is obviously involved in signal transduction processes, very probably has a serine/threonine-kinase function, and plays a presumed role in the formation of cell-cell and/or cell-matrix connections, and/or of desmosomes and/or hemidesmosomes.

[0012] It is known in prior art that serine/threonine-kinases influence the function of cell-cell and cell-matrix contacts in keratinocytes. S. Blum and coauthors demonstrated that the localization of specific cell contact molecules of the *Zonula adherens* can be influenced by activating or inactivating the „protein kinase C (PKC)“-type serine/threonine-kinase (compare Blum S., Ness W., Petrow W., Achenbach F., 1994: *Localization of protein kinase C in primary cultures of human keratinocytes in relation to cell contact proteins.* *Cell Sig.* **6**:157-165). In addition, M. Serres and coauthors showed that treating keratinocytes in a cell culture (HaCaT cells) with the serine/threonine-phosphatase inhibitors okadaic acid, calyculin and PefablocTM results in a loss of cell-cell connections on the one hand, and in an increased serine/threonine phosphorylation of the linker protein β -catenine involved in cellular adhesion (compare

Serres M., Grangeasse C., Haftek M., Durocher Y., Duclos B., Schmitt D., 1997: *Hyperphosphorylation of β -Catenin on serine-threonine residues and loss of cell-cell contacts induced by calyculin A and okadaic acid in human epidermal cells. Exp. Cell. Res.* 231: 163-172). These in-vitro findings were confirmed on epidermal keratinocytes of explanted human skin: a clear disruption of epidermal cell/cell connections with acantholysis occurred after the application of okadaic acid (2 μ M, 24 hours). Neither PKC activators (e.g., bryostatin-1 or TPA=PMA=phorbol myristate acetate) and PKC inhibitors (sphingosine, staurosporine, chelerythrine, H7=1-(5-isoquinoliny)sulfonyl)-2-methylpiperazine) nor inhibitors or activators of protein kinase A (PKA), nor tyrosine-kinase and phosphatase inhibitors or less specific phosphatase inhibitors had such an effect on the cells.

[0013] Serine/threonine kinases also play an important role in the formation of hemidesmosomes (compare Mainiero F., Pepe A., Wary K.K., Spinardi L., Mohammadi M., Schlessinger J. Giancotti F.G., 1995: *Signal transduction by the α 6 β 4 integrin: distinct β 4 subunit sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes.* EMBO J. 14:4470-4481).

[0014] The isolated preparation of protein pKe#122, namely the description of nucleotide sequences that code this protein, and the indication of (one of) its amino acid sequence(s) make it possible to exert a targeted influence on the metabolism of physiologically active or activated keratinocytes, and of course of other cells that express protein pKe#122, in particular for purposes of medical and cosmetic therapy.

[0015] The invention also relates to recombinant DNA vector molecules, which encompass a nucleic acid according to the invention, and which have the ability to express a protein that occurs in human keratinocytes and is increasingly expressed when the keratinocytes are in an activated state, in particular protein pKe#122, in a prokaryotic or eukaryotic cell. The DNA vector molecules preferably involve the plasmid pUEx-1 and/or the plasmid pGEX-2T and/or the plasmid pBK-CMV and/or the plasmid pHR 2 (a derivative of Bluescript KS [Stratagene, Heidelberg], contains the human keratin-14 promoter), since these vectors have proven to be highly suitable in practice. While the eukaryotic cell includes in particular cells from cell cultures, e.g., COS cells, the respective cell can also be a constituent of a living organism, e.g., a transgenic mouse.

[0016] Therefore, the invention also encompasses transformed host cells that contain a nucleic acid according to the invention that is linked with an activatable promotor, which is contained in these cells naturally or as the result of recombination, and that (consequently) have the ability to express a protein that occurs naturally in human keratinocytes and is increasingly expressed when the keratinocytes are in an activated state, in particular protein pKe#122.

[0017] The invention also relates to the use of a nucleic acid according to the invention or a vector molecule according to the invention to manufacture transgenic mammals, in particular mice or rats.

[0018] The transfectants according to the invention open up an opportunity for research and development work aimed at further clarifying the protein pKe#122-induced changes in cell morphology and cellular base functions such as proliferation, adhesion, migration and differentiation, in particular with an eye toward answering the question as to whether protein pKe#122 itself possesses a „pathogenic“ activity.

[0019] The object of this invention also relates to a reagent for the indirect detection of a protein that is encountered in human keratinocytes and increasingly expressed when the keratinocytes are in an activated state, in particular protein pKe#122, wherein this reagent is characterized by the fact that it encompasses at least one nucleic acid according to the invention. In this context, „for the indirect detection“ implies that the protein-coding mRNA is actually directly detected, and hence the protein is only indirectly detected (by means of this mRNA).

[0020] Protein pKe#122 and the polypeptides related thereto, i.e., to the amino acid sequence indicated in the SEQ ID NO:2 sequence protocol or SEQ ID NO:3 sequence protocol, specifically the polypeptides that can be derived through substitution, deletion, insertion and/or inversion from one of these amino acid sequences according to SEQ ID NO:2 or SEQ ID NO:3, or that have an amino acid sequence resulting from a splice variant of an mRNA, which is identical or complementary to the nucleotide sequence indicated in the SEQ ID NO:1 sequence protocol or the SEQ ID NO:4 sequence protocol, or to a partial sequence of these nucleotide sequences, or at least hybridized, offer numerous applications in the area of dermatological research and development. In particular, antibodies can be developed against these polypeptides or proteins, which then can be correspondingly modified for use either as diagnostic or therapeutic agents, or as cosmetic agents („cosmeceuticals“).

[0021] Consequently, the invention also encompasses the use of such a protein or polypeptide for manufacturing a (monoclonal, polyclonal or recombinant) antibody against this polypeptide, the aforementioned antibody itself, and also its use for the diagnostic and/or therapeutic treatment of dermatological diseases, for the cosmetic treatment of the epidermis, and for the diagnostic, therapeutic and/or cosmetic treatment of other tissues or organs that express protein pKe#122.

[0022] According to more recent scientific knowledge, sense and/or antisense oligonucleotides are also possible as active agents for pharmacotherapy (compare G. Hartmann et al. 1998: *Antisense Oligonucleotides*, Deutsches Ärzteblatt 95, Issue 24, C1115-C1119), and also as active agents with a fundamentally new operating principle in pharmacotherapy.

[0023] Therefore, the present invention also relates to the use of sense or antisense oligonucleotides according to the invention for diagnostic and/or therapeutic treatment, in particular of dermatological diseases, or for the cosmetic treatment in particular of the epidermis.

[0024] One technically and economically important potential application for a polypeptide according to the invention or a nucleic acid according to the invention also involves not least the fact that such a molecule can be used in a screening procedure to isolate materials from a very high number of provided materials that specifically bind to the respective nucleic acid or respective polypeptide. These substances can then serve as the parent material (lead structure) for the development of substances for use in pharmacology, and hence offer the preconditions for the development of alternative pharmaceuticals for diagnosis and therapy, in particular with respect to the dermatological diseases mentioned at the outset.

[0025] In this regard, the invention also relates to the application of a polypeptide according to the invention or a nucleic acid according to the invention for identifying substances that can be used in pharmacology, which bind to the polypeptide or nucleic acid, thereby influencing its/their function and/or expression, in particular exerting an inhibiting or activating effect.

[0026] The invention will be explained in greater detail below based on manufacturing and application examples.

Example 1: Manufacture of Protein pKe#122

A) Extraction or Manufacture of a Polynucleotide that Codes Protein pKe#122

[0027] The polynucleotide source consisted of human epidermal keratinocytes of a cell culture or cell culture model described extensively in the publication of Schäfer B.M., Reinartz J., Bechtel M.J., Inndorf S., Lang E., und Kramer M. D., 1996: *Dispace mediated basal detachment of cultured keratinocytes induces urokinase-type plasminogen activator (uPA) and its receptor (uPA-R, CD87)*, *Exp. Cell Res.* 228, pp. 246-253. Reference is hereby made expressly to the content of this publication. This cell culture or cell culture model is characterized by the fact that it makes it possible to convert keratinocytes from the resting $[uPA^-/uPA-R^-]$ to the activated $[uPA^+/uPA-R^+]$ state through enzymatic disruption of the cell/matrix contacts, i.e., dispace-induced detachment of the keratinocytes from the culture matrix. The induction of the activated state is reversible: the (renewed) formation of a confluent (=grown to maximal density), multilayered cell aggregate consisting of differentiated keratinocytes results in the downward adjustment of uPA and uPA-R, i.e., the slowing of production and setting to a lower concentration level (see the publication of Schäfer B.M., Stark H.J., Fusenig N.E., Rodd R.F., Kramer M.D., 1996 *Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system*, *Exp. Cell Res.* 220:415-423).

[0028] Cells in this cell culture or cell culture model shall also be referred to as NHEK below (=„normal human epidermal keratinocytes“).

[0029] The following measures were implemented for preparing the cell culture or cell culture model: Human epidermal keratinocytes obtained from a skin biopsy were trypsinated overnight at 4°C and then cultivated in Petri dishes or 175 cm² culture flasks according to the „feeder-layer“ technique of J.G. Rheinwald and H. Green (1975, *Cell* 6, 331-334) for a duration of 8 days in Dulbecco's modified Eagle's Medium (DMEM) with a content of 10% (vol./vol.) fetal calf serum (FCS) and added adenine hemisulfate, insulin, transferrin, triiodothyronine, hydrocortisone, Forskolin, epidermal growth factor (EGF) and antibiotics (penicillin, streptomycin and gentamycin) under differentiation conditions, namely elevated calcium levels (37 °C, 7% CO₂). Therefore, cultivation took place under conventional conditions common in prior art. Under these conditions,

keratinocytes form confluent two to three-layer „epidermis equivalents“, or keratinocyte „sheets“.

[0030] These epidermis equivalents or keratinocyte sheets were detached from the culture matrix in a 30-minute treatment with dispase II (2.4 mg/ml in DMEM without FCS), washed twice in DMEM and then incubated in complete, conditioned DMEM for a duration of 4 or 8 hours. Incubation in conditioned DMEM took place to preclude the influence of fresh FCS. During incubation, the expression of known activation markers uPA and uPA-R was upwardly adjusted in these floating keratinocyte sheets, as was protein pKe#122 described for the first time herein. The uPA/uPA-R upward adjustment could be detected by means of known techniques, such as enzyme linked immunosorbent assay (ELISA), in-situ hybridization and immune fluorescence. The entire RNA was extracted from the incubated cells ("RNA-Clean" kit, AGS company in Heidelberg) using the guanidinium-thiocyanate-phenol-chloroform extraction method known in the art (compare Chromczynski P. and Sacchi N., 1986: *Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction*. Anal. Biochem. 162:156-159). The mRNA was isolated from the entire RNA through binding on poly-T coated beads. This mRNA was used as the starting material for the ensuing step of subtraction cloning.

[0031] mRNA was isolated from adherent keratinocyte sheets for use in control tests or for comparison preparations, specifically according to the same procedural pattern described above, except that a dispase inhibitor, e.g., phosphoramidone (100 µg/ml), was additionally applied to the dispase for the duration of dispase treatment.

[0032] The principle of subtraction cloning was used to establish a gene bank, which preferably contained cDNA of the dyshesion-induced gene, i.e., of those genes that were increasingly expressed after detachment of the keratinocyte sheets in the latter (or their cells). To this end, the mRNA obtained from the cells of the adherent keratinocyte sheets was again bound to poly-T coated beads, rewritten into single-strand cDNA on the latter, and then hybridized against the mRNA of detached, i.e., non-adherent keratinocyte sheets. Those mRNA molecules that were expressed only in the non-adherent state, i.e., after dyshesion, and hence found no hybridization partner, remained behind as a supernatant. They were rewritten into cDNA and cloned in cloning vector pUEX-1.

[0033] For purposes of verification, the resultant gene bank was then also subjected to a southernblot procedure with [^{32}P]-marked cDNA of adherent and non-adherent keratinocyte sheets. Those cDNA, or rather the host cell clones containing them, here the E. coli strain MC1061, which exhibited a distinct upward adjustment after dyshesion, were subsequently cultivated or multiplied overnight at 30°C under conventional culture conditions. The plasmid DNA (pUEX1-cDNA) were prepared from these E. coli clones. The cDNA fragments were cut out of the pUEX1 vector and were [^{32}P]-marked by means of random priming. The marked cDNA was used as a probe in northernblots with RNA from adherent and non-adherent keratinocyte sheets. The clones containing cDNA, which revealed no or only a slight signal with the RNA of adherent keratinocytes when used as a probe in the northernblot procedure, but exhibited a distinct signal with RNA of non-adherent keratinocytes, were selected for the ensuing step of sequencing.

[0034] While sequencing the respective clones by means of „non-radioactive cycle sequencing“, which is a modification of the sequencing method according to Sanger and has in the meantime become a common method in prior art, the gene with the nucleotide sequence according to SEQ ID NO:1 and SEQ ID NO:4 was found. This gene and the accompanying protein were designated pKe#122. More detailed analyses of the mRNA that belongs to gene pKe#122, i.e., is pKe#122-specific (from dissolved, i.e., non-adherent keratinocyte sheets), provided information as to the fact that this mRNA has a size of roughly 4.8 kb, and exhibits an upward regulation after disperse-induced detachment. Fig. 1 shows the results of a Northern blot, which was performed with mRNA from keratinocyte sheets (a) immediately after or (b) four hours after disperse-induced detachment and with [^{32}P]-marked pKe#122 cDNA. This result indicates that little pKe#122 mRNA was present, or at least detectable, immediately after detachment, while large quantities were present four hours later (a broad, color-intensive band), namely in the molecular weight zone of about 4.8 kb.

[0035] The nucleotide sequence of the pKe#122 gene has a stop codon at the 3' end at position 2373-2375 according to SEQ ID NO:1, and hence at position 2472-2474 according to SEQ ID NO:4, which stipulates the probable location of the transcription end, and which is followed by a sequence very similar to the „polyadenylation site“ (AATAAA), namely AATAA, exactly 28 nucleic acids before the poly-A site.

[0036] As a result with respect to the overall structure of the pKe#122 gene, or in general of a polynucleotide that codes for protein pKe#122, we find that this gene or

polynucleotide has the nucleotide sequence indicated in the SEQ IN NO:1 sequence protocol or the SEQ IN NO:4 sequence protocol, or a partial sequence of one of these two nucleotide sequences, or encompasses a nucleotide sequence or consists of one that is complementary to one of these indicated nucleotide sequences or one of their partial sequences, or that this gene or polynucleotide is wholly or partially hybridized with the nucleotide sequence indicated in the SEQ ID NO:1 sequence protocol or the SEQ ID NO:4 sequence protocol or with a partial sequence of one of these two nucleotide sequences, or with a sequence complementary to these indicated nucleotide sequences or their partial sequences, wherein „U“ can take the place of „T“ in the SEQ ID NO:1 and SEQ ID NO:4 sequence protocols, and that an mRNA corresponding or homologous to a cDNA of approx. 4.8 kb is read from this gene or polynucleotide.

B) Derivation of the Amino Acid Sequence and Characterization of the pKe#122 Protein based on the polynucleotide coded for this purpose (pKe#122 gene)

[0037] Based on the genetic code and using a computer-assisted procedure (program: *HUSAR* = *Heidelberg Unix Sequence Analysis Resources*, Version 4.0, German Cancer Research Center, Heidelberg, 1997), an amino acid sequence indicated in the SEQ ID NO:2 and/or SEQ ID NO:3 sequence protocol was derived from the nucleotide sequence according to the SEQ ID NO:1 and SEQ ID NO:4 sequence protocol. A structural analysis of these amino acid sequences according to the SEQ ID NO:2 and SEQ ID NO:3 sequence protocol with this very program yielded the following information, which is valid for both amino acid sequences:

- the amino acid sequence from position 40 to 63 (LGKGNFAVVKLARHRVTK TQVAIK) according to SEQ ID NO:2, and consequently from position 73 to 96 according to SEQ ID NO:3 corresponds to known protein kinase motifs with ATP binding site,
- the amino acid sequence from position 152 to 164 (IVHRDLKTENLLL) according to SEQ ID NO:2, and consequently from position 185 to 197 according to SEQ ID NO:3 corresponds to known serine/threonine protein kinase motifs,
- the amino acid sequences from position 238 to 240 (TLR), from position 475 to 477 (TGR), from position 485 to 487 (STR) and from position 600 to 603 (TTR) according to SEQ ID NO:2 and from position 271 to 273 (TLR), from position 508 to 510 (TGR), from position 518 to 520 (STR) and from position 633 to 635 (TTR) according to SEQ ID NO:3 correspond to known phosphorylation sites for protein kinase C,

- the amino acid sequence from position 138 to 156 (WQILSAVEYCHDHHIVHRD) according to SEQ ID NO:2 and consequently from position 171 to 189 according to SEQ ID NO:3 represents the pKe#122-1 peptide, against which the anti-peptide antibody „anti-pKe#122-1“ was produced in a rabbit (compare Example 2),
- the amino acid sequence from position 481 to 499 (LAEVSTRLSPLTAPCIVVS) according to SEQ ID NO:2 and consequently from position 514 to 532 according to SEQ ID NO:3 represents the pKe#122-2 peptide, against which the anti-peptide antibody „anti-pKe#122-2“ was produced in a rabbit (compare Example 2).
- the amino acid sequence from position 339 to 352 (NHFAAIYYLLLERL) according to SEQ ID NO:2 and consequently from position 372 to 385 according to SEQ ID NO:3 represents the pKe#122-3 peptide, against which the anti-peptide antibody „anti-pKe#122-3“ was produced in a rabbit (compare Example 2).
- the amino acid sequence from position 614 to 625 (GLARQVCQVPAS) according to SEQ ID NO:2 and consequently from position 647 to 658 according to SEQ ID NO:3 represents the pKe#122-4 peptide, against which the anti-peptide antibody „anti-pKe#122-4“ was produced in a rabbit (compare Example 2).

[0038] In Fig. 2 (for SEQ ID NO:2) and Fig. 14 (for SEQ ID NO:3), these structural data for protein pKe#122 are shown diagrammatically. Fig. 2A and Fig. 14A show the protein kinase motif with ATP binding sites, the serine/threonine protein kinase motif and the four phosphorylation sites for protein kinase C, while Fig. 2B and Fig. 14B show the sequence segments against which anti-peptide antibodies were produced in rabbits.

[0039] Example 2: Use of the Amino Acid Sequence of the pKe#122 Protein for the Manufacture of Polyclonal Anti-Peptide Antibodies

[0040] A computer-assisted antigenicity analysis was performed using the computer program mentioned in Example 1 to select areas from the amino acid sequence according to SEQ ID NO:2 that appeared suitable for the production of polyclonal anti-peptide antibodies. These areas were synthesized according to the known

„multiple-antigenic-peptide“ procedure (compare: Posnett D.N., Tam J.P., 1989: *Multiple antigenic peptide method for producing antipeptide site-specific antibodies*. Methods-Enzymol. 1998; 178: 739-746) in the form of separate peptides (pKe#122-1 to -4, compare Fig. 2) with a molecular weight of approx. 10-15 kD. These peptides were used without the addition of a carrier substance for the adjuvant-assisted immunization of rabbits. The details of this peptide manufacturing procedure and this immunization procedure are generally known in prior art. The pre- and post-immunoserum were tested for reactivity with the respective peptides and comparison peptides used for the immunization by means of the generally known enzyme-linked immunosorbent assay (ELISA). A clear immunization against peptides pKe#122-1, -122-2 and -122-4 could be detected. To purify the polyclonal antibodies, the post-immunoserum were initially subjected to ammonium sulfate precipitation, which enriched the IgG fraction. Immune-affinity chromatography was then carried out with this enriched IgG fraction. To this end, the four peptides pKe#122-1 to -4 used for immunization were immobilized on sepharose 4B, and this peptide-sepharose 4B conjugate was used in immune-affinity chromatography. This resulted in three largely pure anti-peptide IgG fractions, namely anti-peptide pKe#122-1, anti-peptide pKe#122-2 and anti-peptide pKe#122-4. These three affinity-purified antibody fractions showed a clear immune reaction with the respectively corresponding antigen peptide. Table 1 shows these results.

[0041] The immune serum against peptide pKe#122-1, the polyclonal antibody anti-pKe#122-1, was also used to test cell lysates of the keratinocyte line HaCaT and keratinocyte sheets 8 hours after detachment with dispase (=non-adherent keratinocyte sheets) in the Western-blot procedure for the expression of the pKe#122 protein. A band with a molecular weight of approx. 70-85 kD was detected in both the HaCaT cells and the cells of the detached (non-adherent) keratinocyte sheets. The Western-blot used in the experiment is described in detail in Example 3B(2) and depicted on Fig. 3. It exhibits a protein measuring approx. 70-85 kD in both HaCaT cells and in the non-adherent keratinocyte sheets.

[0042] The polyclonal anti-peptide antibody pKe#122-1 was additionally tested in the immunoblot procedure with the recombinant approx. 100 kD GST-pKe#122 fusion protein (fraction 85 in Fig. 10B) described here in Example 5. The polyclonal anti-peptide antibody pKe#122-1 reacted with the fusion protein. This positive reaction was confirmed by a comparison with control tests, in which an anti-GST antibody or normal rabbit IgG was used instead of the anti-peptide antibody pKe#122-1. The results

are presented in Table 1 and on Fig. 4. Trace „a“ on Fig. 4 shows the control batch with normal goat IgG, while trace „d“ on Fig. 4 shows the batch with rabbit anti-pKe#122-1.

[0043] Example 3: Use of the pKe#122 protein either against the protein or against the mRNA of the pKe#122-oriented reagents for detecting the activated state of human epidermal keratinocytes

A) Used Keratinocytes

[0044] The test cells or target cells (=target object cells) were HaCaT cells and human epidermal keratinocytes of the cell culture or the cell culture model (NHEK) that was extensively described in the publication by B.M. Schäfer and coauthors (loco citato) and is briefly summarized here in Example 1 (A). Express reference will be made to the content of this publication at this juncture too. In addition, skin biopsies were analyzed for the expression of the pKe#122 protein.

B) Detection procedures based on the use of antibodies oriented against the pKe#122 protein.

1. Immunohistology

[0045] A cryotom was used to manufacture 5 µm thick frozen sections of tissues from skin biopsies of clinically unpathological, normal skin and clinically pathological, lesional skin owing to the diseases Pemphigus vulgaris, Bullous Pemphigoid and Psoriasis vulgaris. These are dried at room temperature and fixed in 100% acetone (100% methanol, 100% ethanol or 4% paraformaldehyde can be used instead of acetone). The sections are then treated according to the „blocking procedure“ known in prior art to block non-specific binding sites for the antibody. In this example, two blocking steps are performed: (1) blocking with avidin/biotin and (2) blocking with normal serum. In the first blocking step, the avidin/biotin blocking was performed using the avidin-biotin blocking kit from Vector Laboratories according to the manufacturer's instructions, i.e., incubation was performed at room temperature initially for 15 minutes with the avidin finished solution, and then 15 minutes with the biotin finished solution. Subsequently, the sections were incubated with 10 vol.% normal serum in PBS (normal serum of species from which the second antibody originates, here goat normal serum; PBS = phosphate buffered saline, pH 7.2-7.4) for 15 minutes at room temperature.

[0046] After blocking, the sections in PBS are incubated for 1 hour at room temperature with a content of 5 µg/ml anti-peptide pKe#122-1. To remove the unbound antibody, the sections are then washed in PBS with a content of 0.2% (weight/volume) bovine serum albumin. This is followed by incubation, for example with a biotin-labelled antibody from the goat against rabbit IgG (1:500 diluted in PBS/0.2% BSA; 30 minutes at room temperature), another washing step and the application of a streptavidin labelled with the fluorescent dye Cy3 (1:1,000 in PBS/0.2% BSA diluted). A fluorescent dye other than Cy3 can also be used to mark the streptavidin, e.g., FITC. After the last washing step, the sections are covered with a covering agent, e.g., elvanol or histogel, and then analyzed and evaluated under a fluorescence microscope. Fig. 5 shows the results obtained from an immune fluorescence detection performed in this manner: The anti-pKe#122-1 IgG antibody stains keratinocytes on normal skin sections in the area of the epidermal basal membrane zone (Fig. 5A). When dying biopsies of lesional skin caused by the diseases Pemphigus vulgaris (Fig. 5B), Bullous Pemphigoid (Fig. 5C) or Psoriasis vulgaris (Fig. 5D), a distinctively strong coloration is observed in epidermal keratinocytes, in particular in the area of epidermal lesions. Hence, an increased expression and evident upward adjustment of the pKe#122 protein took place there.

2. Immunoblot („Western-blot“) and Dot blot

[0047] Fig. 3 shows the detection of the pKe#122 protein via the Western-blot procedure using anti-pKe#122-1. To this end, cell lysates of the keratinocyte line HaCaT („HaCaT“ samples) and keratinocyte sheets were electrophoretically fractionated 8 hours after dispase treatment („NHEK 8h“ samples) in an SDS polycrylic amide gel. The proteins were blotted on a nitrocellulose membrane according to a standard procedure. To block non-specific binding sites, incubation was performed with a 5 %w/w powdered milk/TBS buffer. Incubation at 4°C for approx. 18 hours (overnight) then was performed on the (protein) strips labeled „anti-122-1“ in a 3% powdered milk/TBS buffer with the addition of anti-pKe#122-1 antibodies (1 µg/ml), and on the (protein)strips labeled „rbIgG“ in a 3% powdered milk/TBS buffer with the addition of rabbit normal IgG (1 µg/ml). The nitrocellulose membrane was then washed with TBS/tween and TBS buffer, and incubated with an enzyme-marked anti-rabbit IgG antibody in a 3% powdered milk/TBS buffer. After renewed washing with TBS/tween and TBS, the bound antibodies were made visible with a peroxidase-specific luminescence substrate (e.g., the ECL system of Amersham-Buchler) and autoradiographically depicted. An alternative marking with chromogenic substrates is also easily possible.

[0048] The cellysates can also be directly blotted onto a nitrocellulose membrane without preceding electrophoretic fractionation and further treated as described above.

3. Enzyme-linked-immunosorbent-assay (ELISA)

[0049] Microtiter plates are coated with recombinant pKe#122/GST fusion protein in various concentrations (10-0 ng/ml). Non-specific binding sites are blocked via treatment with 0.1 %w/w gelatine in PBS (PBS/gelatine). The coated wells were then incubated with anti-pKe#122-1 IgG (1 µg/ml) for 1 hour at room temperature (see Fig. 6 A, closed circles). The control batch takes place with rabbit normal IgG in the same concentrations (see Fig. 6 A, open circles). After a washing step with 0.05 %v/v Tween-20 in PBS (PBS/Tween) is followed by incubation with peroxidase-marked goat-anti-rabbit IgG (1:10,000 in PBS/tween). After another washing step to remove unbound enzyme-marked antibodies, the colorless peroxidase substrate orthophenylene diamine is added, which is converted into a colored product by the peroxidase. Other peroxidase substrates with sharp color change can be used in place of orthophenylene diamine. The color formation, and hence the bound antibody, is quantified by means of an absorption measurement in a microtiter plate photometer at 490 against 405 nm (ordinate). Fig. 6A shows the result of such a test. It shows that the color concentration is proportional to the amount of pKe#122 fusion protein bound to the plate. As a result, an unknown amount of antigen can be quantified by comparison when using samples with known antigen concentrations, so-called standards.

[0050] To quantify the pKe#122 protein in complex solutions, the execution of a sandwich ELISA (Fig. 6B) is preferred. To this end, a microtiter plate is coated with an antibody oriented against pKe#122 (e.g., rabbit anti-pKe#122/GST fusion protein, 1 µg/well). The still remaining non-specific binding sites of the microtiter plate are then blocked with PBS/gelatins. The microtiter plate is subsequently mixed in with various concentrations of the pKe#122/GST protein (10-0 ng/ml). After a washing step with PBS/tween, the plate is incubated with a second peroxidase-marked anti-pKe#122 antibody (e.g., peroxidase-marked rabbit anti-pKe#122-1 (peptide) antibody) (e.g., for one hour while shaking at room temperature). „Peroxidase“ here stands for practically any marking of the antibody, e.g., with enzymes, fluorescence molecules or luminescence molecules. After an additional washing step to remove unbound, enzyme-marked antibodies, the colorless peroxidase substrate orthophenylene diamine is added, which is converted into a colored product by the peroxidase activity. The color

formation is quantified by means of an absorption measurement in a microtiter plate photometer at 490 against 405 nm (ordinate). Fig. 6B shows the result of such a test. It shows that the color concentration is proportional to the amount of pKe#122 bound to the plate. As a result, the unknown quantity of pKe#122 in a sample can be quantified by means of this test procedure. In this case, the substance orthophenylene diamine stands for any desired peroxidase substrate that detectably changes its color due to the peroxidase activity.

[0051] Instead of the polyclonal antibody „anti-pKe#122-1“ used here as an example, use can just as well be made of monoclonal antibodies, which are targeted against the protein pKe#122, namely both in the simple ELISA (=enzyme linked immunosorbent assay) and in the sandwich ELISA.

[0052] Example 4: Detection of pKe#122-specific mRNA in cells via reverse polymerase chain reaction

[0053] The polymerase chain reaction (PCR) was used to detect pKe#122-specific RNA in cells of keratinocyte sheets (NHEK) after disperse treatment and in HaCaT cells. To this end, RNA was isolated from cells of keratinocyte sheets (NHEK) after disperse treatment and incubation times of varying length, and from HaCaT cells using standard methods (guanidinium-thiocyanate-phenol-chloroform extraction method, see also Example 1A) and rewritten to cDNA according to standard methods. This cDNA was subjected to a PCR, during which a partial fragment of ≈ 350 kb was amplified from the pKe#122-specific cDNA. A combination of the primers „pKe#122-forward 3“ (tgagcaggcgctgggtatcatgcag) and „pKe#122-reverse 2“ (tcaccgggaacaagaaggccacct) was used as the primer pair. 10 ng of cDNA were mixed with 10 μ M of primer along with a mixture of heat-stable DNA polymerase, ATP, TTP, GTP, CTP and polymerase buffer (e.g., compare: *Current protocols in Molecular Biology*, Vol. 1, 1997, John Wiley & Sons. Inc, Suppl. 37, Chapter 15), in this example in the form of the commercially available, ready-to-use „PCR master mix“ from Clontech. In addition, the following control tests were performed: 1. The batch described above with the plasmid pUEX-1/pKe#122 instead of the cDNA; 2. The kit-internal positive control; 3. The reaction batch described above without added cDNA (negative control 1); 4. The batch described above with cDNA from cells of keratinocyte sheets (NHEK) 2 hours after disperse treatment, without adding primers (negative control 2). The reaction products of the PCR reaction were electrophoretically fractionated in agarose gel. Fig. 7 shows the results of this fractionation. The following

applies: Trace 1 = molecular weight marker; Trace 2 = NHEK T0; Trace 3 = NHEK T2; Trace 4 = NHEK T4; Trace 5 = NHEK T8; Trace 6 = HaCaT; Trace 7 = free; Trace 8 = positive control (pUEX-1; with pKe#122 as the insert); Trace 9 = negative control (batch with cDNA without primer); Trace 10 = kit-specific positive control for functional check of PCR; Trace 11 = negative control (batch with primer without cDNA); Trace 12 = molecular weight marker. A PCR product of the expected size of \approx 350 kb was detected in traces 3, 4, 5, 6 and 8, meaning that pKe#122-specific mRNA was detected in cells of keratinocyte sheets at time 2 (T2), 4 (T4) and 8 (T8) hours after dispase-induced detachment, and also in HaCaT cells.

[0054] This technique makes it possible to detect the pKe#122 expression even in cases where the pKe#122 protein cannot be detected owing to excessively low expression levels by means of immune histological methods, the ELISA, dotblot or Western-blot procedures.

[0055] Example 5: Manufacture of vector molecules with the ability to express the protein pKe#122 in prokaryotic or eukaryotic cells

[0056] Two approaches were taken to manufacture or express the recombinant pKe#122 protein. In the first, two pKe#122 glutathion-S-transferase (GST) fusion proteins, pKe#122/GST-I and pKe#122/GST-II (vector pGEX; see Fig. 8) were manufactured in bacteria (*E. coli* DH5 α) for purposes of expression. In the second, a pKe#122 FLAG fusion protein (vector pBK-CMV; see Fig. 9) was manufactured in eukaryotic cells (Cells-cells) for purposes of expression.

[0057] The pKe#122-gluthathion-S-transferase (GST) fusion proteins were expressed in *E. coli* (DH5 α) through IPTG induction. After induction, the bacterial lysate was analyzed in a Western blot with anti-GST antibodies, specifically in comparison to pKe#122-gluthathion-S-transferase (GST) vector-carrying, non-induced bacteria lysate, and to lysate of bacteria that expressed only GST. The product of this Western-blot is shown on Fig. 10A: Trace (a) shows the control transfectant (GST without insert) before IPTG induction, trace (b) shows the control transfectant (GST without insert) after IPTG induction, trace (c) shows pKe#122/GST-I before IPTG induction, trace (d) shows pKe#122/GST-I after IPTG induction, trace (e) shows pKe#122/GST-II before IPTG induction, and trace (f) shows pKe#122/GST-II after IPTG induction.

[0058] As evident from the figure, a mixture of GST-positive bands varying in size could be detected, namely exclusively after IPTG induction. The highest molecular band had a molecular weight of approx. 100 kD (fraction 85), the lowest molecular band of approx. 26 kD, which corresponds to the molecular weight of the pure GST protein. The cited data indicate that the recombinant pKe#122-GST fusion protein breaks down in *E. coli*. The expressed fusion proteins (trace d) were present as insoluble protein aggregates in the so-called „inclusion bodies“, so that a prep-cell purification was performed. The fractions of this prep-cell purification were then electrophoretically fractionated using standard procedures, and analyzed by means of the immunoblot procedure already described above using anti-GST antibodies. The product of this purification procedure is shown on Fig. 10B. Purification resulted in a mixture of varying large GST fusion proteins. The thickest band, i.e., the majority of GST fusion proteins, had an apparent molecular weight marker of 65 kD. This allows us to conclude that the 65 kD pKe#122 GST fusion protein consists of the GST protein and an approx. 40 kD large fragment of the protein pKe#122. The 65 kD pKe#122/GST fusion protein was drawn upon to manufacture a polyclonal antiserum in rabbits. The manufacture and characterization of the antibodies took place as described in Example 2 for the anti-peptide antibodies.

[0059] The highest molecular band had an apparent molecular weight of approx. 100 kD (compare Fig. 10 B, fraction 85). This allows us to conclude that the 100 kD pKe#122-GST fusion protein consists of the GST protein and an approx. 70-75 kD large fragment of the pKe#122 protein (compare also Fig. 4 and accompanying description in Example 2).

[0060] In the eukaryotic system, the pBK-CMV-pKe#122 vector (Fig. 9) was transformed into so-called Cos cells, i.e., into cells of the Cos-cell line generally known in prior art. The Cos cells were made to absorb the plasmid-DNA in a standard procedure through treatment with DEAE-dextran/chloroquine. The transformed cells were then incubated for two days under standard conditions (37°C and 7% CO₂). The Cos cells were subjected to lysis and analyzed in the immunoblot procedure using an antibody against the FLAG epitope or the anti-peptide antibody anti-pKe#122-1 IgG. Fig. 11 shows the product of the immunoblot: Trace a shows the non-transfected Cos cells, Trace b shows a FLAG control protein, and Trace c shows Cos cells transfected with pKe#122-FLAG vector construct. Trace c exhibits a band with an approximate molecular weight of 80 kD, which was stained by the anti-FLAG antibody. Trace b

shows a FLAG-marked control protein that demonstrates the functionality of the anti-FLAG antibody.

[0061] Example 6: Influencing of keratinocytes with pKe#122-specific antisense oligonucleotides


[0062] Antisense nucleotides are absorbed by cells, also keratinocytes (compare G. Hartmann et al. 1998: *Antisense-Oligonukleotide*, Deutsches Ärzteblatt 95, Issue 24, C1115-C1119), and bind to the mRNA present in the cell, inhibiting its translation, and hence expression (compare Y.-S. Lee, et al. 1997: *Definition by specific antisense oligonucleotides of a role for protein kinase C α in expression of differentiation markers in normal and neoplastic mouse epidermal keratinocytes*, Molecular Carcinogenesis 18, pp. 44-53). Suitable antisense oligonucleotides were manufactured using the pKe#122-specific nucleotide sequence (SEQ ID NO:1 or SEQ ID NO:4). They were set to a concentration of 100 μ M with a suitable buffer medium (so-called „oligobuffer“). HaCaT cells were cultivated at 37°C and 7% CO₂ up to a confluence of 70-80%. The cells were trypsinated off (10 minutes, 0.2 % EDTA, 5-10 minutes, 0.1 % trypsin) and set to a concentration of 25,000 cells/ml. 100 μ l cell suspension (corresponds to 2,500 cells) was pipetted in per well of a 96-well plate. The cells were incubated for 1 hour, followed by the addition of the antisense oligonucleotide (2 μ l of a 100 μ M solution) and further incubation for 24-48 hours. The negative control consisted of cell batches to which was added an oligonucleotide with the same base distribution, but a randomly selected sequence.

[0063] The cells treated in this manner were analyzed under a microscope for phenotypic changes in the cells. The result of the microscopic analysis is shown on Fig. 12 and Fig. 13: Fig 12 a shows sub-confluent HaCaT cultures that were treated with pKe#122-specific antisense oligonucleotides, Fig. 12 b shows sub-confluent HaCaT cultures treated with control oligonucleotides, Fig. 13 a shows confluent HaCaT cultures treated with pKe#122-specific antisense oligonucleotides, Fig. 13 b shows confluent HaCaT cultures treated with control oligonucleotides, and Fig. 13 c shows a detail section from Fig. 13 a.

[0064] The results of microscopic analysis demonstrate that, in comparison to control oligonucleotides, the number of cells in the cultures treated with the specific antisense-oligonucleotide is distinctly reduced. This allows us to conclude that the cellular proliferation was diminished by the antisense-oligonucleotide. After confluence

had been reached, the HaCaT cultures treated with antisense-oligonucleotides exhibited greatly enlarged cells, which were not discovered in the cultures treated with control oligonucleotides. These large cells correspond to differentiated keratinocytes in terms of their morphology. The findings allow us to conclude that cells treated with pKe#122-specific antisense-oligonucleotides show an increased tendency toward differentiation.

[0065] In sum, treatment with pKe#122-specific oligonucleotides has a distinct influence on proliferation and differentiation.



Rec'd PCT/PTO

09/10/559
18 JUN 2001

SEQUENCE LISTING

<110> Kramer, Michael

<120> Regulatory Protein from Keratinocytes

<130> KM1/PCT

<140> PCT/DE 99/02865

<141> 1999-09-06

<150> DE19842863.4

<151> 1998-09-19

<160> 4

<170> PatentIn Ver. 2.1

<210> 1

<211> 2533

<212> DNA

<213> Homo sapiens

<400> 1

```
ggcaccagg tgcgcgcgga gccatgggta tcatgtcgga gttcagcgcg gaccccgcg 60
gccagagtca gggccagcag aagccccctc ggggtgggtt ttacgacatc gagcggaccc 120
tgggcaaagg caacttcgcg gtgggtgaagc tggcgcggca tcgagtcacc aaaacgcagg 180
ttgcaataaa aataattgat aaaacacgat tagattcaag caatttggag aaaatctatc 240
gtgaggttca gctgatgaag cttctgaacc atccacacat cataaagctt taccagggtta 300
tggaacaaa ggacatgctt tacatcgta ctgaatttgc taaaaatgga gaaatgtttg 360
attatttgac ttccaacggg cacctgagtg agaacgaggc gcggaagaag ttctggcaaa 420
tcctgtcgcg cgtggagtac tgtcacgacc atcacatcgt ccaccgggac ctcaagaccg 480
agaacctcct gctggatggc aacatggaca tcaagctggc agattttgga tttgggaatt 540
tctacaagtc aggagagcct ctgtccacgt ggtgtgggag ccccccgat gccgccccgg 600
aagtctttga ggggaaggag tatgaaggcc cccagctgga catctggagc ctgggcgtgg 660
tgctgtacgt cctgggtctgc ggttctctcc ccttcgatgg gcctaacctg ccgacgctga 720
gacagcgggg gctggagggc cgttcccgca tccccctctt catgtctcaa gactgtgaga 780
gcctgatccg ccgcatgctg gtgggtggacc ccgccaggcg catcaccatc gccagatcc 840
ggcagcaccg gtggatgcgg gctgagccct gcttgccggg accgcctgc cccgccttct 900
ccgcacacag ctacacctcc aacctgggcg actacgatga gcaggcgctg ggtatcatgc 960
agacctggg cgtggaccgg cagaggacgg tggagtcact gcaaaacagc agctataacc 1020
actttgctgc cattttattac ctctctcttg agcggctcaa ggagtatcgg aatgccagc 1080
gcgcccggcc cgggcctgcc aggcagccgc ggccctggag ctccggacctc agtggtttgg 1140
aggtgcctca ggaaggctct tccaccgacc ctttccgacc tgccttgctg tgcccgcagc 1200
cgcagacctt ggtgcagtcg gtcctccagg ccgagatgga ctgtgagctc cagagctcgc 1260
tgcagtggcc cttgttcttc ccggtggatg ccagctgcag cggagtgttc cggccccggc 1320
ccgtgtcccc aagcagcctg ctggacacag ccatcagtga ggaggccagg caggggcccgg 1380
gcctagagga ggagcaggac acgcaggagt ccctgccag cagcacgggc cggaggcaca 1440
ccctggccga ggtctccacc cgcctctccc cactcaccgc gccatgtata gtcgtctccc 1500
cctccaccac ggcaagtcc gacagaggaa ccagctctga cagttgtctg accttctctg 1560
cgagcaaaag ccccgcgggg ctcaagtggc ccccgccac tcaggggctg ctgggcgcct 1620
gctccccggg caggctggcc tcgcccttcc tggggctgca gtccgccacc ccagtgtctg 1680
aggctcaggg gggcttggga ggagctgttc tgctccctgt cagcttccag gagggacggc 1740
gggcgtcgga cacctcactg actcaagggc tgaaggcctt tcggcagcag ctgaggaaga 1800
ccacgcggag caaagggttt ctgggactga acaaaatcaa ggggctggct cgccaggtgt 1860
gccaggtccc tgccagccgg gccagcagg gcggcctgag ccccttccac gccctgcac 1920
agagcccagg cctgcacggc gcgcgagcg gcgcgcggga gggctggagc ctgctggagg 1980
aggtgctaga gcagcagagg ctgctccagt tacagcacca cccggccgct gcacccggct 2040
gctcccaggc cccccagccg gccctgccc cgtttgtgat cggccctgt gatggccctg 2100
gggtgcggcc gctcccagc acctcctca cgtcggggct cccgctgctg ccgccccac 2160
tcctgcagac cggcgcgtcc ccctggcct cagcggcgca gctcctggac acacacctgc 2220
```

PatentIn Ver. 2.1

```

acattggcac cggccccacc gccctccccg ctgtgcccc accacgcctg gccaggctgg 2280
ccccaggttg tgagcccctg gggctgctgc agggggactg tgagatggag gacctgatgc 2340
cctgctccct aggcacgttt gtccctggtgc agtgagggca gccctgcatc ctggcacgga 2400
cactgactct tacagcaata acttcagagg aggtgaagac atctggcctc aaagccaaga 2460
actttctaga agcgaaataa gcaatacgtt aggtgttttg gcgaaaaaaa aaaaaaaaaa 2520
aaaaaaaaaa aaa                                     2533

```

```

<210> 2
<211> 790
<212> PRT
<213> Homo sapiens

```

```

<220>
<223> Serine/Threonine kinase motif

```

```

<220>
<223> 4 Tyrosine kinase phosphorylation sites

```

```

<220>
<223> Kinase domain with ATP-binding site

```

```

<400> 2
His Pro Gly Ala Arg Gly Ala Met Val Ile Met Ser Glu Phe Ser Ala
  1               5               10               15
Asp Pro Ala Gly Gln Ser Gln Gly Gln Gln Lys Pro Leu Arg Val Gly
          20               25               30
Phe Tyr Asp Ile Glu Arg Thr Leu Gly Lys Gly Asn Phe Ala Val Val
          35               40               45
Lys Leu Ala Arg His Arg Val Thr Lys Thr Gln Val Ala Ile Lys Ile
          50               55               60
Ile Asp Lys Thr Arg Leu Asp Ser Ser Asn Leu Glu Lys Ile Tyr Arg
          65               70               75               80
Glu Val Gln Leu Met Lys Leu Leu Asn His Pro His Ile Ile Lys Leu
          85               90               95
Tyr Gln Val Met Glu Thr Lys Asp Met Leu Tyr Ile Val Thr Glu Phe
          100              105              110
Ala Lys Asn Gly Glu Met Phe Asp Tyr Leu Thr Ser Asn Gly His Leu
          115              120              125
Ser Glu Asn Glu Ala Arg Lys Lys Phe Trp Gln Ile Leu Ser Ala Val
          130              135              140
Glu Tyr Cys His Asp His His Ile Val His Arg Asp Leu Lys Thr Glu
          145              150              155              160
Asn Leu Leu Leu Asp Gly Asn Met Asp Ile Lys Leu Ala Asp Phe Gly
          165              170              175
Phe Gly Asn Phe Tyr Lys Ser Gly Glu Pro Leu Ser Thr Trp Cys Gly
          180              185              190
Ser Pro Pro Tyr Ala Ala Pro Glu Val Phe Glu Gly Lys Glu Tyr Glu

```

195	200	205
Gly Pro Gln Leu Asp Ile Trp Ser Leu Gly Val Val Leu Tyr Val Leu		
210	215	220
Val Cys Gly Ser Leu Pro Phe Asp Gly Pro Asn Leu Pro Thr Leu Arg		
225	230	235
Gln Arg Val Leu Glu Gly Arg Phe Arg Ile Pro Phe Phe Met Ser Gln		
245	250	255
Asp Cys Glu Ser Leu Ile Arg Arg Met Leu Val Val Asp Pro Ala Arg		
260	265	270
Arg Ile Thr Ile Ala Gln Ile Arg Gln His Arg Trp Met Arg Ala Glu		
275	280	285
Pro Cys Leu Pro Gly Pro Ala Cys Pro Ala Phe Ser Ala His Ser Tyr		
290	295	300
Thr Ser Asn Leu Gly Asp Tyr Asp Glu Gln Ala Leu Gly Ile Met Gln		
305	310	315
Thr Leu Gly Val Asp Arg Gln Arg Thr Val Glu Ser Leu Gln Asn Ser		
325	330	335
Ser Tyr Asn His Phe Ala Ala Ile Tyr Tyr Leu Leu Leu Glu Arg Leu		
340	345	350
Lys Glu Tyr Arg Asn Ala Gln Cys Ala Arg Pro Gly Pro Ala Arg Gln		
355	360	365
Pro Arg Pro Arg Ser Ser Asp Leu Ser Gly Leu Glu Val Pro Gln Glu		
370	375	380
Gly Leu Ser Thr Asp Pro Phe Arg Pro Ala Leu Leu Cys Pro Gln Pro		
385	390	395
Gln Thr Leu Val Gln Ser Val Leu Gln Ala Glu Met Asp Cys Glu Leu		
405	410	415
Gln Ser Ser Leu Gln Trp Pro Leu Phe Phe Pro Val Asp Ala Ser Cys		
420	425	430
Ser Gly Val Phe Arg Pro Arg Pro Val Ser Pro Ser Ser Leu Leu Asp		
435	440	445
Thr Ala Ile Ser Glu Glu Ala Arg Gln Gly Pro Gly Leu Glu Glu Glu		
450	455	460
Gln Asp Thr Gln Glu Ser Leu Pro Ser Ser Thr Gly Arg Arg His Thr		
465	470	475
Leu Ala Glu Val Ser Thr Arg Leu Ser Pro Leu Thr Ala Pro Cys Ile		
485	490	495
Val Val Ser Pro Ser Thr Thr Ala Ser Pro Ala Glu Gly Thr Ser Ser		
500	505	510

Asp Ser Cys Leu Thr Phe Ser Ala Ser Lys Ser Pro Ala Gly Leu Ser
 515 520 525
 Gly Thr Pro Ala Thr Gln Gly Leu Leu Gly Ala Cys Ser Pro Val Arg
 530 535 540
 Leu Ala Ser Pro Phe Leu Gly Ser Gln Ser Ala Thr Pro Val Leu Gln
 545 550 555 560
 Ala Gln Gly Gly Leu Gly Gly Ala Val Leu Leu Pro Val Ser Phe Gln
 565 570 575
 Glu Gly Arg Arg Ala Ser Asp Thr Ser Leu Thr Gln Gly Leu Lys Ala
 580 585 590
 Phe Arg Gln Gln Leu Arg Lys Thr Thr Arg Thr Lys Gly Phe Leu Gly
 595 600 605
 Leu Asn Lys Ile Lys Gly Leu Ala Arg Gln Val Cys Gln Val Pro Ala
 610 615 620
 Ser Arg Ala Ser Arg Gly Gly Leu Ser Pro Phe His Ala Pro Ala Gln
 625 630 635 640
 Ser Pro Gly Leu His Gly Gly Ala Ala Gly Ser Arg Glu Gly Trp Ser
 645 650 655
 Leu Leu Glu Glu Val Leu Glu Gln Gln Arg Leu Leu Gln Leu Gln His
 660 665 670
 His Pro Ala Ala Ala Pro Gly Cys Ser Gln Ala Pro Gln Pro Ala Pro
 675 680 685
 Ala Pro Phe Val Ile Ala Pro Cys Asp Gly Pro Gly Ala Ala Pro Leu
 690 695 700
 Pro Ser Thr Leu Leu Thr Ser Gly Leu Pro Leu Leu Pro Pro Pro Leu
 705 710 715 720
 Leu Gln Thr Gly Ala Ser Pro Val Ala Ser Ala Ala Gln Leu Leu Asp
 725 730 735
 Thr His Leu His Ile Gly Thr Gly Pro Thr Ala Leu Pro Ala Val Pro
 740 745 750
 Pro Pro Arg Leu Ala Arg Leu Ala Pro Gly Cys Glu Pro Leu Gly Leu
 755 760 765
 Leu Gln Gly Asp Cys Glu Met Glu Asp Leu Met Pro Cys Ser Leu Gly
 770 775 780
 Thr Phe Val Leu Val Gln
 785 790

<210> 3
 <211> 823

<212> PRT
<213> Homo sapiens

<220>
<223> Serine/Threonine kinase motif

<220>
<223> 4 Tyrosine kinase phosphorylation sites

<220>
<223> kKinase domaine with ATP binding site

<400> 3

```
Pro Glu Ala Ala Ala Ala Ala Ala Ala Ala Gly Ala Val Gly Thr Arg
  1             5             10             15

Ala Ala Pro Ala Ala Glu Arg Ala Ala Ser Trp Pro Gly Arg Ser Gly
      20             25             30

Gly Gly Gly Gly Ala Arg Gly Ala Met Val Ile Met Ser Glu Phe Ser
      35             40             45

Ala Asp Pro Ala Gly Gln Ser Gln Gly Gln Gln Lys Ser Leu Arg Val
      50             55             60

Gly Phe Tyr Asp Ile Glu Arg Thr Leu Gly Lys Gly Asn Phe Ala Val
      65             70             75             80

Val Lys Leu Ala Arg His Arg Val Thr Lys Thr Gln Val Ala Ile Lys
      85             90             95

Ile Ile Asp Lys Thr Arg Leu Asp Ser Ser Asn Leu Glu Lys Ile Tyr
      100            105            110

Arg Glu Val Gln Leu Met Lys Leu Leu Asn His Pro His Ile Ile Lys
      115            120            125

Leu Tyr Gln Val Met Glu Thr Lys Asp Met Leu Tyr Ile Val Thr Glu
      130            135            140

Phe Ala Lys Asn Gly Glu Met Phe Asp Tyr Leu Thr Ser Asn Gly His
      145            150            155            160

Leu Ser Glu Asn Glu Ala Arg Lys Lys Phe Trp Gln Ile Leu Ser Ala
      165            170            175

Val Glu Tyr Cys His Asp His His Ile Val His Arg Asp Leu Lys Thr
      180            185            190

Glu Asn Leu Leu Leu Asp Gly Asn Met Asp Ile Lys Leu Ala Asp Phe
      195            200            205

Gly Phe Gly Asn Phe Tyr Lys Ser Gly Glu Pro Leu Ser Thr Trp Cys
      210            215            220

Gly Ser Pro Pro Tyr Ala Ala Pro Glu Val Phe Glu Gly Lys Glu Tyr
      225            230            235            240

Glu Gly Pro Gln Leu Asp Ile Trp Ser Leu Gly Val Val Leu Tyr Val
      245            250            255
```


Leu Val Cys Gly Ser Leu Pro Phe Asp Gly Pro Asn Leu Pro Thr Leu
260 265 270

Arg Gln Arg Val Leu Glu Gly Arg Phe Arg Ile Pro Phe Phe Met Ser
275 280 285

Gln Asp Cys Glu Ser Leu Ile Arg Arg Met Leu Val Val Asp Pro Ala
290 295 300

Arg Arg Ile Thr Ile Ala Gln Ile Arg Gln His Arg Trp Met Arg Ala
305 310 315 320

Glu Pro Cys Leu Pro Gly Pro Ala Cys Pro Ala Phe Ser Ala His Ser
325 330 335

Tyr Thr Ser Asn Leu Gly Asp Tyr Asp Glu Gln Ala Leu Gly Ile Met
340 345 350

Gln Thr Leu Gly Val Asp Arg Gln Arg Thr Val Glu Ser Leu Gln Asn
355 360 365

Ser Ser Tyr Asn His Phe Ala Ala Ile Tyr Tyr Leu Leu Leu Glu Arg
370 375 380

Leu Lys Glu Tyr Arg Asn Ala Gln Cys Ala Arg Pro Gly Pro Ala Arg
385 390 395 400

Gln Pro Arg Pro Arg Ser Ser Asp Leu Ser Gly Leu Glu Val Pro Gln
405 410 415

Glu Gly Leu Ser Thr Asp Pro Phe Arg Pro Ala Leu Leu Cys Pro Gln
420 425 430

Pro Gln Thr Leu Val Gln Ser Val Leu Gln Ala Glu Met Asp Cys Glu
435 440 445

Leu Gln Ser Ser Leu Gln Trp Pro Leu Phe Phe Pro Val Asp Ala Ser
450 455 460

Cys Ser Gly Val Phe Arg Pro Arg Pro Val Ser Pro Ser Ser Leu Leu
465 470 475 480

Asp Thr Ala Ile Ser Glu Glu Ala Arg Gln Gly Pro Gly Leu Glu Glu
485 490 495

Glu Gln Asp Thr Gln Glu Ser Leu Pro Ser Ser Thr Gly Arg Arg His
500 505 510

Thr Leu Ala Glu Val Ser Thr Arg Leu Ser Pro Leu Thr Ala Pro Cys
515 520 525

Ile Val Val Ser Pro Ser Thr Thr Ala Ser Pro Ala Glu Gly Thr Ser
530 535 540

Ser Asp Ser Cys Leu Thr Phe Ser Ala Ser Lys Ser Pro Ala Gly Leu
545 550 555 560

Ser Gly Thr Pro Ala Thr Gln Gly Leu Leu Gly Ala Cys Ser Pro Val
565 570 575

Arg Leu Ala Ser Pro Phe Leu Gly Ser Gln Ser Ala Thr Pro Val Leu
 580 585 590
 Gln Ala Gln Gly Gly Leu Gly Gly Ala Val Leu Leu Pro Val Ser Phe
 595 600 605
 Gln Glu Gly Arg Arg Ala Ser Asp Thr Ser Leu Thr Gln Gly Leu Lys
 610 615 620
 Ala Phe Arg Gln Gln Leu Arg Lys Thr Thr Arg Thr Lys Gly Phe Leu
 625 630 635 640
 Gly Leu Asn Lys Ile Lys Gly Leu Ala Arg Gln Val Cys Gln Val Pro
 645 650 655
 Ala Ser Arg Ala Ser Arg Gly Gly Leu Ser Pro Phe His Ala Pro Ala
 660 665 670
 Gln Ser Pro Gly Leu His Gly Gly Ala Ala Gly Ser Arg Glu Gly Trp
 675 680 685
 Ser Leu Leu Glu Glu Val Leu Glu Gln Gln Arg Leu Leu Gln Leu Gln
 690 695 700
 His His Pro Ala Ala Ala Pro Gly Cys Ser Gln Ala Pro Gln Pro Ala
 705 710 715 720
 Pro Ala Pro Phe Val Ile Ala Pro Cys Asp Gly Pro Gly Ala Ala Pro
 725 730 735
 Leu Pro Ser Thr Leu Leu Thr Ser Gly Leu Pro Leu Leu Pro Pro Pro
 740 745 750
 Leu Leu Gln Thr Gly Ala Ser Pro Val Ala Ser Ala Ala Gln Leu Leu
 755 760 765
 Asp Thr His Leu His Ile Gly Thr Gly Pro Thr Ala Leu Pro Ala Val
 770 775 780
 Pro Pro Pro Arg Leu Ala Arg Leu Ala Pro Gly Cys Glu Pro Leu Gly
 785 790 795 800
 Leu Leu Gln Gly Asp Cys Glu Met Glu Asp Leu Met Pro Cys Ser Leu
 805 810 815
 Gly Thr Phe Val Leu Val Gln
 820

<210> 4

<211> 2632

<212> DNA

<213> Homo sapiens

<400> 4

ccccggagggc agcagcagcg gcgggcggcag ccggagcagt aggcacccga gcagcgccag 60

cgcccgagcg	ggcggttcc	tggcctgggc	gctccggtgg	cgccggaggt	gcgcgcggag	120
ccatgggttat	catgtcggag	ttcagcgcgg	accccgcggg	ccagagtcag	ggccagcaga	180
agtcctcccg	ggtgggtttt	tacgacatcg	agcggaccct	gggcaaaggc	aacttcgcgg	240
tggatgaagct	ggcgcgccat	cgagtcacca	aaacgcaggt	tgcaataaaa	ataattgata	300
aaacacgatt	agattcaagc	aattttggaga	aaatctatcg	tgaggttcag	ctgatgaagc	360
ttctgaacca	tccacacatc	ataaagcttt	accaggttat	ggaaacaaag	gacatgcttt	420
acatcgtcac	tgaatttgct	aaaaatggag	aaatgtttga	ttatttgact	tccaacgggc	480
acctgagtg	gaacgaggcg	cgaagaagt	tctggcaaat	cctgtcggcc	gtggagtact	540
gtcacgacca	tcacatcgtc	caccgggacc	tcaagaccga	gaacctcctg	ctggatggca	600
acatggacat	caagctggca	gattttggat	ttgggaattt	ctacaagtca	ggagagcctc	660
tgctccacgtg	gtgtgggagc	cccccgtag	ccgccccgga	agtctttgag	gggaaggagt	720
atgaaggcct	ccagctggag	atctggagcc	tgggcgtggt	gctgtacgtc	ctgggtctgcg	780
gttctctccc	cttcgatggg	cctaacctgc	cgacgctgag	acagcgggtg	ctggagggcc	840
gcttccgcat	ccccctcttc	atgtctcaag	actgtgagag	cctgatccgc	cgcatgctgg	900
tggatggacc	cgccaggcgc	atcaccatcg	cccagatccg	gcagcaccgg	tggatgcggg	960
ctgagccctg	cttgccggga	cccgctgccc	ccgcttcttc	cgcacacagc	tacacctcca	1020
acctgggcca	ctacgatgag	caggcgctgg	gtatcatgca	gacctggggc	gtggaccggc	1080
agaggacggt	ggagtcactg	caaaacagca	gctataacca	ctttgctgcc	atttattacc	1140
tcctccttga	gcggctcaag	gagtatcgga	atgcccagtg	cgcccgcccc	gggcctgcca	1200
ggcagcccg	gcctcggagc	tcggacctca	gtggtttgga	ggtgcctcag	gaagggtctt	1260
ccaccgacct	ttcccgacct	gccttgctgt	gcccgcagcc	gcagaccttg	gtgcagtcctg	1320
tcctccaggc	cgagatggac	tgtgagctcc	cgagctcgct	gcagtgggcc	ttgttcttcc	1380
cggtggatgc	cagctgcagc	ggagtgttcc	ggccccggcc	cgtgtcccca	agcagcctgc	1440
tggacacagc	catcagttag	gaggccaggc	aggggcgggg	cctagaggag	gagcaggaca	1500
cgcaggagtc	cctgcccagc	agcacggggc	ggaggcacac	cctggccgag	gtctccacc	1560
gcctctcccc	actcaccgcg	ccatgtatag	tgtctcccc	ctccaccacg	gcaagtccctg	1620
cagagggaac	cagctctgac	agttgtctga	ccttctctgc	gagcaaaaagc	ccgcgggggc	1680
tcagtggcac	cccggccact	caggggctgc	tgggcgcctg	ctccccgggc	aggctggcct	1740
cgcccttcc	ggggtcgcag	tccgccaccc	cagtgtgca	ggctcagggg	ggcttgggag	1800
gagctgttct	gctccctgtc	agcttccagg	agggacggcg	ggcgtcggac	acctcactga	1860
ctcaagggtc	gaaggccttt	cggcagcagc	tgaggaagac	cacgcggacc	aaagggtttc	1920
tgggactgaa	caaaatcaag	gggctggctc	gccagggtgtg	ccaggctcct	gccagccggg	1980
ccagcagggg	cggcctgagc	cccttccacg	cccctgcaca	gagcccaggc	ctgcacggcg	2040
gcgcagccgg	cagccgggag	ggctggagcc	tgttgaggga	ggtgctagag	cagcagaggc	2100
tgctccagtt	acagcaccac	ccggccgctg	caccggctg	ctcccaggcc	ccccagccgg	2160
ccccgcccc	gtttgtgatc	gccccctgtg	atggccctgg	ggctgccccg	ctccccagca	2220
ccctcctcac	gtcggggctc	ccgctgctgc	cgccccact	cctgcagacc	ggcgcgtccc	2280
cggtgccctc	agcggcgag	ctcctggaca	cacacctgca	cattggcacc	ggccccaccg	2340
ccctccccgc	tgtgccccca	ccacgcctgg	ccaggctggc	cccaggttgt	gagccccctg	2400
ggctgctgca	gggggactgt	gagatggagg	acctgatgcc	ctgctcccta	ggcacgtttg	2460
tcctggtgca	gtgagggcag	ccctgcaccc	tggcacggac	actgactctt	acagcaataa	2520
cttcagagga	ggtgaagaca	tctggcctca	aagccaagaa	ctttctagaa	gcgaaataag	2580
caatacgtta	ggtgttttgg	cgaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aa	2632

CLAIMS

1. Isolated polypeptide,

which is identical or similar to a protein that occurs naturally in human keratinocytes and is increasingly expressed when the keratinocytes are in an activated state, and

which has the amino acid sequence indicated in either the SEQ ID NO:2 sequence protocol or the SEQ ID NO:3 sequence protocol, or representing an allele or derivative obtained through amino acid substitution, deletion, insertion or inversion from one of these two amino acid sequences.

2. Isolated nucleic acid

that encodes a protein,

which is identical or similar to a protein that occurs naturally in human keratinocytes and is increasingly expressed when the keratinocytes are in an activated state,

which has the nucleotide sequence indicated in either the SEQ ID NO:1 sequence protocol or the SEQ ID NO:4 sequence protocol,

or a nucleotide sequence complementary to one of these two,

or a partial sequence of one of these two indicated or complementary nucleotide sequences,

or a nucleotide sequence that hybridizes wholly or in part with one of these aforementioned nucleotide sequences.

3. Isolated nucleic acid according to claim 2, characterized by the fact that this nucleic acid is obtained from a natural, synthetic or half-synthetic source.

4. Isolated nucleic acid according to claim 2 or 3, characterized by the fact that this nucleic acid is a cDNA.
5. Isolated nucleic acid according to one of claims 2 or 3, characterized by the fact that this nucleic acid is a sense or antisense oligonucleotide, which encompasses at least 6, preferably 8 to 25 nucleotides, and hybridizes with the nucleotide sequence indicated in sequence protocol SEQ ID NO:1 or sequence protocol SEQ ID N:4 or partial sequences thereof.
6. Isolated nucleic acid according to one of claims 2 or 3, characterized by the fact that this nucleic acid is a splice variant, which hybridizes with the nucleotide sequence indicated in sequence protocol SEQ ID NO:1 or in sequence protocol SEQ ID NO:4.
7. Isolated polypeptide, characterized by the fact that

it has an amino acid sequence resulting from a splice variant of an mRNA, which

has either the nucleotide sequence indicated in sequence protocol SEQ ID NO:1 or in sequence protocol SEQ ID NO:4,

or the nucleotide sequence complementary to one of these two,

or a partial sequence of one of these two indicated or complementary nucleotide sequences,

or a nucleotide sequence that hybridizes wholly or in part with one of these aforementioned nucleotide sequences.
8. Recombinant DNS vector molecule, which encompasses a nucleic acid according to one of claims 2 to 6, and which has the ability to express a protein that occurs in human keratinocytes and is increasingly expressed when the keratinocytes are in an activated state, in particular protein pKe#122, in a prokaryotic or eukaryotic cell.

9. Recombinant DNS vector molecule according to claim 8, characterized by the fact that the vector molecule is the plasmid pUEX-1 or pGEX-2T or pBK-CMV or pHR2.
10. Transformed host cell containing a nucleic acid according to one of claims 2 to 6, which is coupled with an activatable promotor contained in the host cell naturally or as the consequence of a recombination, and which has the ability to express a protein that occurs in human keratinocytes and is increasingly expressed when the keratinocytes are in an activated state, in particular protein pKe#122.
11. Transformed host cell according to claim 10, characterized by the fact that the promotor is the cytokeratin-14 promotor and the host cell is a keratinocyte, or that the promotor is the CMV promotor and the host cell is a Cos cell.
12. Use of a nucleic acid according to claim 2 or a vector molecule according to claim 8 for manufacturing transgenic mammals, in particular mice or rats.
13. Use of a polypeptide according to claim 1 or claim 7 for manufacturing an antibody against this polypeptide and/or proteins related thereto.
14. Use according to claim 13, characterized by the fact that the antibody is used for the diagnostic and/or therapeutic treatment in particular of dermatological diseases, or for the cosmetic treatment in particular of the epidermis.
15. Antibody that reacts specifically with a polypeptide according to claim 1 or claim 7.
16. Use of an antibody according to claim 15 for the diagnostic and/or therapeutic treatment of dermatological diseases, or for the cosmetic treatment of the epidermis.
17. Reagent for the indirect detection of a protein that occurs in human keratinocytes and is increasingly expressed in activated keratinocytes, in particular protein pKe#122, characterized by the fact that the reagent encompasses at least one nucleic acid according to one of claims 2 to 6 or a polypeptide according to claim 1 or claim 7.

18. Use of a sense or antisense oligonucleotide according to claim 5 for the diagnostic and/or therapeutic treatment in particular of dermatological diseases, or for the cosmetic treatment in particular of the epidermis.
19. Use of a polypeptide according to claim 1 or claim 7 or a nucleic acid according to claim 2 for identifying substances with medical, cosmetic or pharmacological applications, which bind to the polypeptide or nucleic acid, and thereby influence its function and/or expression, in particular acting as inhibitors or activators.

Abstract

The invention relates to an isolated polypeptide which is equivalent to or similar (i.e., equivalent in function and effect) to a protein which is naturally occurring in human keratinocytes and which is increasingly expressed in the activated state of the keratinocytes. The invention also relates to an isolated nucleic acid encoding such a polypeptide or protein typical of human keratinocytes, as well as to the use of said polypeptide and said nucleic acid for the purpose of assays, particularly for diagnostic purposes, and/or for therapeutic purposes, or to the use of reagents, particularly of recombinant vector molecules and antibodies directed against such molecules. The inventive protein has an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:3 of the sequence listing or an allele or derivative of said amino acid sequence derived by amino acid substitution, deletion, insertion or inversion. The inventive nucleic acid has a nucleotide sequence as depicted in SEQ ID NO:1 or SEQ ID NO:4 of the sequence listing or a nucleotide sequence complementary thereto or a partial sequence of one of these nucleotide sequences or a nucleotide sequence which fully or partially hybridizes to any of the above-mentioned nucleotide sequences.

Table 1

Characterization of the anti-peptide antibodies. From the respective sera the IgG fractions were enriched by means of ammonium sulfate precipitation. The respective IgG preparations were tested with the corresponding and with the irrelevant peptides by means of a peptide-ELISA. In a further step the IgG preparations were tested also with the purified fusion protein GST-pKe#122-1 by means of an Immuno-Blot.

IgG-preparation	reactivity in the peptide ELISA	reactivity in the Immuno-Blot (with GST-pKe#122-1)
anti-peptide #122-1	+	+
anti-peptide #122-2	+	-
anti-peptide #122-3	-	n.p.
anti-peptide #122-4	+	-

"+"=reactivity; "-"= no reactivity; "n.p."= not performed; *) see also Fig. 4




Fig.1




Fig. 2




Fig.3




Fig.4




Fig. 5

7/15




Fig. 6




Fig.7

9/15

BamH1 pKe#122/GST-I: bp 287-2339 EcoR1
pKe#122/GST-II: bp 287-1094




Fig.8




Fig. 9




Fig.10

12/15




Fig.11




Fig. 12




Fig. 13





Fig.14



DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **REGULATORY PROTEIN FROM HUMAN KERATINOCYTES**, the specification of which (check one)

- ☒ is attached hereto
☒ was filed on 6 September 1999 as International Application Serial No. PCT/DE99/02865
and was amended on _____ (if applicable).
☒ I hereby authorize and request our attorney, Davidson, Davidson & Kappel, LLC. of 485 Seventh Avenue, 14th Floor, New York, New York 10018 to insert here in parentheses (Application number _____, filed _____) the filing date and application number of said application when known.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information which is known to me to be material to the patentability of this application as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign and/or provisional application(s) for patent or inventor's certificate listed below and have also identified below any foreign and/or provisional application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

PRIOR APPLICATION(S)			Priority claimed
<u>19842863.4</u>	<u>Germany</u>	<u>19 September 1998</u>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
(Number)	(Country)	(Day/Month/Year Filed)	
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
(Number)	(Country)	(Day/Month/Year Filed)	

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial Number)	(Filing Date)	(Status) (patented, pending, abandoned)
_____	_____	_____
(Application Serial Number)	(Filing Date)	(Status) (patented, pending, abandoned)

And I hereby appoint Clifford M. Davidson, Registration No. 32,728, Leslye B. Davidson, Registration No. 38,854, Cary S. Kappel, Registration No. 36,561, William C. Gehris, Registration No. 38,156, Morey B. Wildes, Registration No. 36,968, Robert J. Paradiso, Registration No. 41,240, Erik R. Swanson, Registration No. 40,833, Scott L. Appelbaum, Registration No. 41,587, Cynthia R. Moore, Registration No. 46,086, David Knasiak, Registration No. 45,991, Salvatore J. Maiorino, Registration No. 42,830, my attorneys, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith; correspondence address: DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 Seventh Avenue, 14th Floor, New York, New York 10018; Telephone: (212) 736-1940; Fax: (212) 736-2427.


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first
Inventor Michael KRAMER
Inventor's signature [Signature]
Date 3.5.01
Residence Pfungstadt, Germany
Citizenship German
Post Office Address: Bergstrasse 85
64319 Pfungstadt, Germany

Full name of joint
Inventor, if any Jeanette REINARTZ
Third Inventor's signature [Signature]
Date May 18 2001
Residence Heidelberg, Germany
Citizenship German
Post Office Address: Angelweg 2
D-69121 Heidelberg, Germany

Full name of joint
Inventor, if any Michael BECHTEL
Second Inventor's signature [Signature]
Date 11.05.01
Residence Schriesheim, Germany
Citizenship German
Post Office Address: Edelsteinstrasse
D-69198 Schriesheim, Germany

Full name of joint
Inventor, if any Birgit SCHAEFFER
Fourth Inventor's signature [Signature]
Date May 15 2001
Residence Heidelberg, Germany
Citizenship German
Post Office Address: Odenwaldstrasse 49/2
D-69124 Heidelberg, Germany



Full name of joint
Inventor Reinhard WALLICH
Fifth Inventor's signature R. Wallich
Date May 14
Residence Heidelberg, Germany DEX
Citizenship German
Post Office Address: Hermann-Loens-Weg 52/1
D-69118 Heidelberg, Germany

Full name of joint
Inventor, if any _____

Seventh Inventor's signature _____
Date _____
Residence _____
Citizenship _____
Post Office Address: _____


Full name of joint
Inventor, if any _____

Sixth Inventor's signature _____
Date _____
Residence _____
Citizenship _____
Post Office Address: _____

Full name of joint
Inventor, if any _____

Eighth Inventor's signature _____
Date _____
Residence _____
Citizenship _____
Post Office Address: _____

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

There were 14 pages of drawing
and page 2 is fig 1 .

☒ Scanned copy is best available. drawings.